Bi-weekly: Thursdays, 12 pm EDT/EST, 9 am PT/PST, 5 pm BST/BDT, 6 pm CEST/CET
https://dfci.zoom.us/webinar/register/WN_m7JJaw52T8yZYt8-ykL6UQ
Some seminars were recorded and accessible for a limited time on our youtube channel.
Upcoming Speakers
April 3rd, 2025
Host: Katherine Donovan / Mikołaj Słabicki
Peng Chen
Peking University
Targeted Protein Degradation in the Transmembrane and Extracellular Space
Dr. Peng Chen is the Boya Distinguished Professor and Chair of Chemical Biology at Peking University, Senior Investigator at Shenzhen Bay Laboratory, and the New Cornerstone Investigator from the New Cornerstone Foundation. Before joining Peking University in 2009, he obtained Ph.D with Prof. Chuan He at The University of Chicago and finished postdoctoral training with Prof. Peter Schultz at The Scripps Research Institute. He is currently also the Director of Chemical Biology Division at Chinese Chemical Society and the Executive Editor at ACS Chemical Biology.
His group is interested in developing and applying new chemistry tools to investigate protein-based interactions and activities in living systems. He has been leading the development of bioorthogonal cleavage reactions, which has enabled the gain-of-function study of proteins as well as other biomolecules in living cells and animals. This has created a new direction in bioorthogonal chemistry with broad utilities in life sciences and medicine. He is also interested in developing cutting-edge technology for membrane protein degradation.
Chase Suiter
University of Washington
Combinatorial mapping of E3 ubiquitin ligases to their target substrates
Chase Suiter is a graduate student in Dr. Jay Shendure’s lab at the University of Washington, where he develops technologies to study the regulation of protein degradation. As part of his graduate work, he created COMET, a high-throughput method for identifying E3 ubiquitin ligase substrates, which also incorporates a systematic evaluation of computational protein structure prediction for E3-substrate interactions. His research has been supported by an NIH NHLBI F31 Award. Prior to graduate school, Chase worked as a research technician in Dr. Jun J. Yang’s lab at St. Jude Children’s Research Hospital and earned his undergraduate degree from the University of Mississippi.
April 17th, 2025
Host: Shourya S Roy Burman / Zuzanna Kozicka
Charlotte Crowe
University of Dundee
Mechanisms of degrader-targeted protein ubiquitinability
Dr Charlotte Crowe is a postdoctoral researcher in Alessio Ciulli’s laboratory at the Centre for Targeted Protein Degradation (CeTPD) at the University of Dundee. She is originally from Strasbourg, France. She moved to Scotland in 2015 to study an MChem in Chemistry at the University of St Andrews, graduating with Honours in 2020. Her PhD, focusing on using chemical, structural and biophysical approaches to understand the mechanism of action of small molecule degraders in Targeted Protein Degradation (TPD), with a particular focus on Cullin RING E3 ligases, was supervised by Professor Alessio Ciulli and Professor Ron Hay at the University of Dundee, and Dr Hannah Maple from Tocris, Bio-Techne. In 2024, she joined the Ciulli lab as a postdoctoral researcher, and from January 2025 she has been working in the CeTPD LITE project team with the Michael J. Fox Foundation developing degraders to tackle Parkinson’s disease.
TBC
TBC
TBC
TBC
May 1st, 2025
Host: Hubert Huang
Larry Hamann
Interdict Bio
Sequence-Selective Translation Inhibition as a Novel, Proximity-Based Cancer Therapeutic Modality
Larry Hamann is currently co-founder, president and CEO of Interdict Bio, pioneering small-molecule context-dependent translation inhibitors for addressing historically undruggable targets in oncology and neurodegeneration. Previously, he was Global Head of Discovery at Takeda. Prior to Takeda, he was Corporate VP and Global Head of Small Molecule Drug Discovery at Celgene, and prior to Celgene, stints at Novartis, Bristol-Myers Squibb and Ligand. In >30 years in drug discovery, his teams have advanced >22 molecules into the clinic, including ONGLYZA™, DAKLINZA™, and branaplam, as well as mezigdomide, golcadomide, and gridegalutamide - targeted protein degraders all currently in Phase III. He is co-inventor on >70 patents, co-author on >90 scientific publications, and advises many biotechs and VCs. He is a recipient of the ACS Heroes of Chemistry Award, the ACS Division of Medicinal Chemistry Award, and was inducted into the Medicinal Chemistry Hall of Fame. Larry holds a Ph.D. in organic chemistry from the University of Michigan.
TBC
TBC
TBC
TBC
May 15th, 2025
Host: Katherine Donovan
Rebecca Metivier
DFCI
Integrated high-throughput proteomics platform for degrader target discovery and validation.
Rebecca received her BS in Marine Biology from Roger Williams University and her MS in Chemical Biology from Boston College. After receiving her Masters, Rebecca worked as a Research associate in the proteomics group in the Center for Protein degradation where she focused on target identification using established methodology as well as leading the development of new workflows within the group. Rebecca joined the the TPD Proteomics Core as a Scientist in 2021 where she employs various chemoproteomics methods to study cellular responses to protein degraders and molecular glues. She also leads the development and optimization of new methods and technologies for the group.
Martin Steger
NEOsphere Biotechnologies
Integrated high-throughput proteomics platform for degrader target discovery and validation.
-
PhD in molecular cancer research from the University of Zurich (Switzerland)
-
Postdoc at the MPI of Biochemistry in Martinsried (Germany), working on Parkinson's disease and using global proteomics and phosphoproteomics to discover the first molecular marker for LRRK2 protein kinase
-
Currently industry researcher (Head of Degrader Biochemistry and Co-founder) at NEOsphere Biotechnologies, using state-of-the-art proteomics methods for screening protein degraders and validating target candidates of degraders.
May 29th, 2025
Host: Zuzanna Kozicka
tba
tba
tba
tba
tba
tba
tba
tba​